CBIO

Crescent Biopharma, Inc. Common Stock

12.96 USD
-0.54
4.00%
At close Jul 11, 4:00 PM EDT
After hours
12.96
+0.00
0.00%
1 day
-4.00%
5 days
-18.75%
1 month
-21.93%
3 months
-35.81%
6 months
-48.35%
Year to date
-49.24%
1 year
-55.96%
5 years
-96.66%
10 years
-98.30%
 

About: Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

0
Funds holding %
of 7,312 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.58% more ownership

Funds ownership: 47.07% [Q4 2024] → 47.66% (+0.58%) [Q1 2025]

15% less capital invested

Capital invested by funds: $7.56M [Q4 2024] → $6.46M (-$1.1M) [Q1 2025]

17% less funds holding

Funds holding: 41 [Q4 2024] → 34 (-7) [Q1 2025]

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

50% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 12

54% less call options, than puts

Call options by funds: $24K | Put options by funds: $52K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$22
70%
upside
Avg. target
$25
93%
upside
High target
$28
116%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Stifel
Stephen Willey
116%upside
$28
Buy
Initiated
25 Jun 2025
LifeSci Capital
Charles Zhu
70%upside
$22
Outperform
Initiated
18 Jun 2025

Financial journalist opinion

Charts implemented using Lightweight Charts™